Can Fite Biopharma (NYSEMKT: CANF) reported Q4 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Can Fite Biopharma earnings for the quarter were N/A. In the same quarter last year, Can Fite Biopharma's earnings per share (EPS) was N/A.
As of Q2 2024, Can Fite Biopharma's earnings has grown year over year. Can Fite Biopharma's earnings in the past year totalled -$7.63 million.
What was CANF's revenue last quarter?
Can Fite Biopharma (NYSEMKT: CANF) reported Q4 2023 revenue of N/A up N/A year over year. In the same quarter last year, Can Fite Biopharma's revenue was N/A.
What was CANF's revenue growth in the past year?
As of Q2 2024, Can Fite Biopharma's revenue has grown -8.27% year over year. This is 157.24 percentage points lower than the US Biotechnology industry revenue growth rate of 148.97%. Can Fite Biopharma's revenue in the past year totalled $743.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.